Major Survival Benefit in Prostate Cancer Patients Announced

• LuPIN drug combination of Veyonda and Lu-PSMA-617 (Novartis) results in half of all patients surviving at least 19.7 months, a ground-breaking outcome for men with end-stage (Stage 4) disease and no remaining treatment options • Data being presented to global cancer conference (11-13 February 2021) • Noxopharm undertaking strategic discussions with respect to making LuPIN treatment a new standar